VADUZ, Liechtenstein, Oct. 31, 2025 /PRNewswire/ — RefluxStop® Nears FDA Approval – Strong Momentum Toward US Market Entry Significant events in the third quarter of 2025 Received positive feedback from the FDA on the final […]
Tag: Implantica
Implantica publishes Interim Report January – September 2025 (Q3)
VADUZ, Liechtenstein, Oct. 31, 2025 /PRNewswire/ — RefluxStop® Nears FDA Approval – Strong Momentum Toward US Market Entry Significant events in the third quarter of 2025 Received positive feedback from the FDA on the final […]
Implantica publishes Interim Report January – September 2025 (Q3)
VADUZ, Liechtenstein, Oct. 31, 2025 /PRNewswire/ — RefluxStop® Nears FDA Approval – Strong Momentum Toward US Market Entry Significant events in the third quarter of 2025 Received positive feedback from the FDA on the final […]
Implantica Successfully Completes MDSAP Recertification Audit
VADUZ, Liechtenstein, Oct. 6, 2025 /PRNewswire/ — Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment […]
Implantica publishes Interim Report January
VADUZ, Liechtenstein, Nov. 15, 2024 /PRNewswire/ — RefluxStop™ achieves crucial FDA milestone and leaps forward with strong momentum in both the US and Europe Significant events in the third quarter of 2024 First national RefluxStop™ […]
